Sona Nanotech Inc (TSE:SONA) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Sona Nanotech Inc. has announced that its innovative gold nanorod-based targeted hyperthermia therapy (THT) has shown promising results in treating melanoma in preclinical trials, following success with triple negative breast cancer. The therapy, possibly enhanced by a second dose of near-infrared light, not only performed well alone but also demonstrated a significant synergistic effect when combined with standard immunotherapy. These findings bolster the company’s plan to advance towards human clinical trials for treating solid cancers like late-stage melanoma.
For further insights into TSE:SONA stock, check out TipRanks’ Stock Analysis page.
